Beam Therapeutics reported Q4 2025 license and collaboration revenue of USD 114.1 million (up 279.5%) and R&D expenses of USD 99.3 million (down 2.1%), with G&A expenses of USD 32.3 million (up 12.6%). Net income attributable to common stockholders in Q4 was USD 244.3 million, or USD 2.37 per basic share and USD 2.33 per diluted share. For FY 2025, Beam reported license and collaboration revenue of USD 139.7 million (up 120.0%), R&D expenses of USD 409.6 million (up 11.4%), and G&A expenses of USD 113.8 million (up 2.1%). Net loss attributable to common stockholders for FY 2025 was USD 80.0 million, or USD 0.81 per share. Beam ended 2025 with cash, cash equivalents and marketable securities of USD 1.25 billion. On the business side, Beam announced a new liver-targeted genetic disease program, BEAM-304, for phenylketonuria (PKU), with an IND filing anticipated in 2026 and an initial Phase 1/2 focus on patients with the R408W mutation. The company also said it is on track to report updated Phase 1/2 data and next steps for pivotal development for BEAM-302 in alpha-1 antitrypsin deficiency by the end of Q1 2026, expects initial clinical data for BEAM-301 in glycogen storage disease type Ia in 2026, and expects to submit a BLA for risto-cel in sickle cell disease as early as year-end 2026. Beam also disclosed a strategic financing agreement with Sixth Street providing up to USD 500 million in non-dilutive capital, and said its expected cash runway is now into mid-2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240701PRIMZONEFULLFEED9659427) on February 24, 2026, and is solely responsible for the information contained therein.